ROCKVILLE, Md., Dec. 9 /PRNewswire-FirstCall/ -- Novavax, Inc.
(Nasdaq: NVAX) and the
The preclinical study evaluated the immunogenicity and efficacy of the RSV VLP vaccine candidate in mice. The VLP contains the matrix (i.e., "core") protein of Newcastle Disease Virus decorated with a human RSV attachment glycoprotein (Ga), which is important for inducing immunity against RSV. In this study, mice were immunized with one of four doses of the RSV VLP vaccine candidate, inactivated RSV, live RSV, or a placebo. The antibody responses to the RSV VLPs were robust and higher than the antibody responses to inactivated or live RSV. Further, antibody titers increased with higher VLP doses.
Subsets of mice that had been immunized with either RSV VLPs via intraperitoneal inoculation or live RSV via intranasal inoculation received a vaccine booster dose and were challenged with live RSV intra-nasally. Unimmunized mice were evaluated as controls. The VLP-immunized mice were protected from RSV replication in the lungs. Further, the lung tissue of these mice showed no evidence of enhanced inflammation after RSV challenge/infection, which has been reported with a formalin-inactivated RSV vaccine.
In summary, the candidate VLP vaccine induced strong antibody responses
against RSV, protected mice against RSV replication i
|SOURCE Novavax, Inc.|
Copyright©2008 PR Newswire.
All rights reserved